- Home
- ENTA vs GPMT Comparison
ENTA vs GPMT Comparison
Compare ENTA & GPMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- GPMT
- Stock Information
- Founded
- ENTA 1995
- GPMT 2015
- Country
- ENTA United States
- GPMT United States
- Employees
- ENTA N/A
- GPMT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- GPMT Real Estate Investment Trusts
- Sector
- ENTA Health Care
- GPMT Real Estate
- Exchange
- ENTA Nasdaq
- GPMT Nasdaq
- Market Cap
- ENTA 154.0M
- GPMT N/A
- IPO Year
- ENTA 2013
- GPMT 2017
- Fundamental
- Price
- ENTA $5.59
- GPMT $2.60
- Analyst Decision
- ENTA Buy
- GPMT Buy
- Analyst Count
- ENTA 4
- GPMT 3
- Target Price
- ENTA $17.25
- GPMT $3.38
- AVG Volume (30 Days)
- ENTA 228.9K
- GPMT 295.3K
- Earning Date
- ENTA 05-05-2025
- GPMT 05-06-2025
- Dividend Yield
- ENTA N/A
- GPMT 7.65%
- EPS Growth
- ENTA N/A
- GPMT N/A
- EPS
- ENTA N/A
- GPMT N/A
- Revenue
- ENTA $66,590,999.00
- GPMT N/A
- Revenue This Year
- ENTA N/A
- GPMT N/A
- Revenue Next Year
- ENTA N/A
- GPMT $31.28
- P/E Ratio
- ENTA N/A
- GPMT N/A
- Revenue Growth
- ENTA N/A
- GPMT N/A
- 52 Week Low
- ENTA $4.71
- GPMT $2.46
- 52 Week High
- ENTA $17.80
- GPMT $4.74
- Technical
- Relative Strength Index (RSI)
- ENTA 31.66
- GPMT 33.70
- Support Level
- ENTA $5.65
- GPMT $2.67
- Resistance Level
- ENTA $5.96
- GPMT $2.77
- Average True Range (ATR)
- ENTA 0.36
- GPMT 0.09
- MACD
- ENTA -0.15
- GPMT -0.02
- Stochastic Oscillator
- ENTA 4.77
- GPMT 11.09
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.